It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Delve into a zero based budgeting case study that showcases real results. Gain insights to enhance your budgeting efforts.
21,278 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Costco posted solid June numbers, with a 10.6% rise in sales and a strong e-commerce lift. Yet the stock declined, si...
A leading career expert warns that overreliance on AI could dull judgment and make skilled workers more vulnerable to...
Empery Digital has sold a sizable block of its bitcoin holdings, joining a broader trend among corporate treasuries m...
When a biotech firm nears a major FDA decision, every insider transaction can feel like a tell. This article dives in...
Amazon stock defies volatility with strong AWS momentum and AI commitments, fueling a growing conviction among trader...
Markets are watching the Fed's next move as rate hikes loom. This guide explains how the pattern of interest rates so...
Oil prices climb as U.S.-Iran tensions raise the risk of supply disruption through the Strait of Hormuz. Gas prices t...
Two popular 2x silver ETFs tumble in 2026 as volatility and decay erode leverage. AGQ and ZSL illustrate why daily re...
A small group of retirees collects about $62,172 yearly from Social Security by following a strict earnings and claim...
JPMorgan Chase delivered a record-breaking second quarter in 2026, topping expectations across the board. CEO Jamie D...
A retired couple confronts a familiar retirement puzzle: stay in a costly, large home or downsize, even as borrowing ...